Literature DB >> 10733554

Fas-mediated cholangiopathy in the murine model of graft versus host disease.

Y Ueno1, M Ishii, K Yahagi, Y Mano, N Kisara, N Nakamura, T Shimosegawa, T Toyota, S Nagata.   

Abstract

Bile-duct injury observed in hepatic graft versus host disease (GVHD) is regarded as an immune-mediated injury, although its precise mechanism is unclear. However, recent studies have suggested the involvement of Fas-mediated cell death in this immune-mediated cholangiopathy. In this study, we first showed the constitutive expression of Fas receptor by cholangiocytes in situ from normal BALB/c mice, which was upregulated in GVHD mice. Also, we confirmed the Fas protein expression in the isolated cholangiocytes from normal BALB/c mice by immunocytochemistry and immunoblotting. Furthermore, the addition of agonistic Fas antibody-(Jo2)-induced cholangiocyte apoptosis confirmed by DNA-ladder formation and annexin V staining. Cholangiocytes from Fas-deficient mice (MRL lpr/lpr) did not show Jo2-induced apoptosis. Interferon-gamma augmented Fas expression and Fas-mediated cell death, respectively. Following these observations, experimental GVHD was induced by transfer of splenocytes from B10.D2 mice to irradiated (800 rad) BALB/c mice. Liver-infiltrating lymphocytes from the recipient showed dose-dependent cytotoxicity against (51)Cr-labeled cholangiocytes isolated from BALB/c mice. Moreover, the addition of blocking Fas-Fc fusion protein reduced this cytotoxicity to 44.7%. Finally, administration of this Fas-Fc protein to the BALB/c mice, which had been adoptively transferred with splenocytes of B10.D2 mice, prevented the development of hepatic GVHD in vivo. These results showed the involvement of Fas-mediated cell death in cholangiopathy observed in GVHD, and a soluble Fas-Fc protein may have a therapeutic potential for hepatic GVHD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733554     DOI: 10.1053/he.2000.5764

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

Review 1.  Bioinformatic approach for understanding the heterogeneity of cholangiocytes.

Authors:  Koji Fukushima; Yoshiyuki Ueno
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

2.  Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.

Authors:  J G Lunz; S Contrucci; K Ruppert; N Murase; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 3.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 4.  The pathophysiology of acute graft-versus-host disease.

Authors:  James L M Ferrara; Kenneth R Cooke; Takanori Teshima
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 5.  Pathophysiology of acute graft-versus-host disease: recent advances.

Authors:  Yaping Sun; Isao Tawara; Tomomi Toubai; Pavan Reddy
Journal:  Transl Res       Date:  2007-07-03       Impact factor: 7.012

Review 6.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 7.  Cell death and cell death responses in liver disease: mechanisms and clinical relevance.

Authors:  Tom Luedde; Neil Kaplowitz; Robert F Schwabe
Journal:  Gastroenterology       Date:  2014-07-18       Impact factor: 22.682

8.  PBC: Animal Models of Cholangiopathies and Possible Endogenous Viral Infections.

Authors:  Masashi Ninomiya; Yoshiyuki Ueno; Tooru Shimosegawa
Journal:  Int J Hepatol       Date:  2011-08-08

Review 9.  Immune mediated liver failure.

Authors:  Xiaojing Wang; Qin Ning
Journal:  EXCLI J       Date:  2014-10-01       Impact factor: 4.068

Review 10.  Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.

Authors:  Dhifaf Sarhan; Padraig D'Arcy; Andreas Lundqvist
Journal:  Int J Mol Sci       Date:  2014-10-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.